Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc., a clinical-stage biotechnology company, is making significant strides with its lead product candidate, ADI-001, demonstrating strong efficacy in treating both lupus nephritis and systemic lupus erythematosus, which may bolster its market position in the autoimmune sector. The anticipated initiation of a Phase 1 study for ADI-212 targeting metastatic castration-resistant prostate cancer in 2026 indicates further expansion into oncology, adding potential high-value milestones to the company's pipeline. Additionally, Adicet’s strategy to partner with third-party manufacturers for commercial-scale production mitigates manufacturing risks, enhancing operational efficiency and positioning the company favorably for future growth opportunities.

Bears say

Adicet Bio Inc is projected to incur a net loss of $1.13 per share by 2025, raising concerns about its financial sustainability as it navigates a challenging clinical development landscape. Key risks include potential negative clinical data, slower-than-expected progress in clinical trials, and increased regulatory hurdles, particularly as no gamma-delta T-cell therapies have received FDA approval to date. Furthermore, the reduction in the probability of success for its candidate ADI-001 in certain autoimmune conditions to 15%, coupled with heightened competition, suggests a potential for diminished market share and revenue, contributing to a negative outlook on the company's financial future.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Jan 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.